Does Dexamethasone Work in Combination With Lenalidomide, Ixazomib in Newly Diagnosed Multiple Myeloma? The MM-6 Trial 15 Key Statistics from…
Browsing: Multiple Myeloma
The GRIFFIN Study is a post-hoc analysis of sustained MRD negative status in the griffin study which treated patients with…
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, Haematologist with clinical and research interests in multiple myeloma, in particular myeloma, lymphoma…
The study that I will be discussing today is the frailty subgroup analysis of the CANDOR study, which is a…
Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and…
Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and…
Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about…
Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about…
Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at…
Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at…
Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he…
Jens Hillengass, MD, Ph.D., Chief of Myeloma, Professor of Oncology at Roswell Park Comprehensive Cancer Center. In this video, he…
Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division…
Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division…
Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH…
Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH…
Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from…
Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from…
Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus…
Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus…
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84…
Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84…
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He…
Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He…
Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the…
Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about Minimal Residual Disease in Myeloma: Application for…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about Minimal Residual Disease in Myeloma: Application for…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about MMRF CureCloud – First At-home Genomic Testing…
Daniel Auclair, Ph.D., Chief Scientific Officer, The Multiple Myeloma Research Foundation speaks about MMRF CureCloud – First At-home Genomic Testing…
Taiga Nishihori, MD from the H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract -…
Taiga Nishihori, MD from the H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract -…
Brian Durie, MD, part of the iStopMM team and chairman of the International Myeloma Foundation speaks about the study -…
Mounzer Agha, MD, is the director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center, and…
Saad Usmani, FACP, MBA, MD from the Department of Hematologic Oncology and Blood Disorders, Atrium Health’s Levine Cancer Institute speaks…
Saad Usmani, FACP, MBA, MD from the Department of Hematologic Oncology and Blood Disorders, Atrium Health’s Levine Cancer Institute speaks…
Dan Sherbenou, MD, Ph.D. from the University of Colorado Medical Campus, Division of Hematology Research, Sherbenou Lab speaks about Older…
Li Du, Ph.D. City of Hope speaks about AACR 2021 Abstract – 1329 – SUMOylation Inhibition Overcomes Dexamethasone Resistance In…
Dawn Marie Stull Medical Science Liaison at Takeda Pharmaceuticals speaks about Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple…
Alessandra Larocca, MD, Ph.D. from the University of Torino, AOU S.Giovanni Battista, TORINO, Italy speaks about Dose/Schedule-Adjusted Rd-R vs Continuous…
Paul G. Richardson, MD from Dana-Farber Cancer Institute speaks about FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class…
Drs. Aggarwal and West welcome Dr. Vincent Rajkumar, Professor of Medicine and multiple myeloma from Mayo Clinic, as they discuss…
Enrique M. Ocio, MD, Ph.D. of the Marqués de Valdecilla University Hospital discusses ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and…
Dr. Irene Ghobrial and Dr. Karen Winkfield give us guidance on a basic action we can all take to help…
Dr. Irene Ghobrial and Dr. Karen Winkfield discuss the ground-breaking study on the disease that will aid in developing new…
Dr. Irene Ghobrial and Dr. Karen Winkfield discuss the markers surrounding the disease and those people most at risk for…
Dr. Irene Ghobrial and Dr. Karen Winkfield describe the symptoms of the disease and how their research study is aiding…
Dr. Irene Ghobrial and Dr. Karen Winkfield talk about the necessity for research to stem the incidence of multiple myeloma
Omar Nadeem, MD from Dana-Farber Cancer Institute speaks about HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory…